WallStSmart

Fox Corp Class A (FOXA)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 282% more annual revenue ($63.32B vs $16.58B). PFE leads profitability with a 11.8% profit margin vs 11.4%. PFE appears more attractively valued with a PEG of 13.77. PFE earns a higher WallStSmart Score of 55/100 (C).

FOXA

Buy

53

out of 100

Grade: C-

Growth: 4.0Profit: 7.0Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: 2.44

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 5.3Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FOXAUndervalued (+31.9%)

Margin of Safety

+31.9%

Fair Value

$89.80

Current Price

$62.94

$26.86 discount

UndervaluedFair: $89.80Overvalued
PFEUndervalued (+29.4%)

Margin of Safety

+29.4%

Fair Value

$37.48

Current Price

$25.68

$11.80 discount

UndervaluedFair: $37.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FOXA2 strengths · Avg: 8.0/10
P/E RatioValuation
15.0x8/10

Attractively priced relative to earnings

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$150.92B9/10

Large-cap with strong market position

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

FOXA4 concerns · Avg: 2.5/10
Revenue GrowthGrowth
2.0%4/10

2.0% revenue growth

PEG RatioValuation
14.322/10

Expensive relative to growth rate

EPS GrowthGrowth
-35.8%2/10

Earnings declined 35.8%

Free Cash FlowQuality
$-773.00M2/10

Negative free cash flow — burning cash

PFE3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : FOXA

The strongest argument for FOXA centers on P/E Ratio, Price/Book.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : FOXA

The primary concerns for FOXA are Revenue Growth, PEG Ratio, EPS Growth.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

FOXA carries more volatility with a beta of 0.53 — expect wider price swings.

PFE is growing revenue faster at 5.4% — sustainability is the question.

PFE generates stronger free cash flow (2.2B), providing more financial flexibility.

Monitor ENTERTAINMENT industry trends, competitive dynamics, and regulatory changes.

Bottom Line

PFE scores higher overall (55/100 vs 53/100). FOXA offers better value entry with a 31.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fox Corp Class A

COMMUNICATION SERVICES · ENTERTAINMENT · USA

Fox Corporation is an American mass media company headquartered in New York City.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?